Ser309

Site Information
sDDsPARsVQsAAVP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18015719

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 3 ) , cervical adenocarcinoma ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , HeLa (cervical) ( 4 ) , HeLa S3 (cervical) ( 3 ) , WM239A (melanocyte) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
4	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info